<DOC>
	<DOCNO>NCT02264665</DOCNO>
	<brief_summary>A descriptive , prospective ( partly retrospective ) , multisite , observational study conduct France adult patient treat well differentiate , unresectable metastatic , pancreatic neuroendocrine tumor disease progression .</brief_summary>
	<brief_title>Observational Study In Real Life Settings Of The Systemic Treatment Of Well Differentiated , Unresectable Or Metastatic , Progressive Pancreatic Neuroendocrine Tumors ( pNET ) : A Study Of Morbidity And Mortality At 2 Years</brief_title>
	<detailed_description>prospective retrospective Analyses perform use SAS® software</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients 18 year age ; Patients treat targeted therapy ( sunitinib , everolimus ) treatment ( interferon , metabolic radiotherapy , chemotherapy somatostatin analog ) * : *Patients whose treatment line ( targeted therapy treatment ) initiate 1st , 2nd , 3rd 4th line therapy time inclusion ( incident patient ) patient receive 1st , 2nd , 3rd 4th line therapy provide treatment initiated site patient enrol study ( prevalent patient ) ; change line define change molecule combination . A histologically confirm unresectable metastatic pancreatic neuroendocrine tumor ; Well‐differentiated ; Progressive prior initiation treatment investigator 's judgment ( clinical radiological progression ) ; Patients inform condition study sign informed consent . Patients diagnosis poorly differentiate neuroendocrine carcinoma adenoneuroendocrine carcinoma . Patients receive target therapy ( everolimus sunitinib ) already receive previous line treatment ( rechallenged patient ) . Patients refuse give consent . Patients receive fifth line subsequent line systemic treatment . Patients participate clinical trial treatment arm validate MA TNCD accord version date December 2013 . Patients randomize placebo arm placebo‐controlled trial double‐blind trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>